Roadmap

IMML Roadmap: Achieving Immortality

2024-2025: Establishment and Foundation

Q3 2024

-  IMML Launch: Creation of the IMML cryptocurrency and implementation of the DAO.

- Initial Partnerships: Formalization of partnerships with renowned universities and research institutes.

- Token Distribution: Launch of the IMML token and initial distribution campaign.

Q4 2024

- Initial Funding: Allocation of initial funds to research projects focused on AI, nanotechnology, and robotics.

- Creation of Multisig Wallet: Implementation of a multisig wallet for secure fund management.

2025-2026: Research and Development

Q1 2025

- AI Projects Launch: Initiation of AI-focused projects for genetic data analysis and personalized therapy development.

- Nanotechnology Research Start: Funding of research on nanorobots for cellular repair and immune system enhancement.

Q2 2025

- Medical Robotics Development: Launch of projects to create medical robotic devices and automated research platforms.

- Education Platform: Creation of an online platform to democratize access to knowledge and resources on longevity and immortality.

Q3 2025

- First Results Published: Release of the first results from IMML-funded research.

- Partnership Expansion: Inclusion of more research institutions and universities worldwide.

Q4 2025

- Progress Evaluation: Review of ongoing projects and funding adjustments based on obtained results.

2026-2027: Technological Advances and Clinical Applications

Q1 2026

- Nanorobots Testing: Initial clinical trials of nanorobots for cellular repair in animal models.

- Advanced AI Development: Implementation of more advanced AI algorithms to improve diagnostics and therapies.

Q2 2026

- International Collaboration: Establishment of collaborative networks among researchers globally to accelerate advancements.

- Robotics Innovations: Prototyping robots for minimally invasive medical interventions.

Q3 2026

- Clinical Studies Publication: Disclosure of preliminary results from nanorobot studies.

- Governance Improvement: Implementation of governance structure improvements for the DAO based on community feedback.

Q4 2026

- Education and Training: Launch of online courses and training for healthcare professionals on newly developed technologies.

2027-2028: Implementation and Expansion

Q1 2027

- Initial Human Trials: Beginning of initial clinical trials of nanorobots in humans.

- AI in Clinical Practice: Integration of AI tools into clinical practices for disease diagnosis and treatment.

Q2 2027

- Genetic Research Expansion: Additional funding for genetic editing research to reverse aging.

- Brain-Machine Interface Development: Pilot projects to connect AI to the human neocortex.

Q3 2027

- Hospital Partnerships: Collaborations with hospitals to test emerging technologies in clinical settings.

- Community Feedback: Implementation of systems to collect continuous feedback from IMML participants.

Q4 2027

- Progress Review: Comprehensive evaluation of advancements and impact of developed technologies.

2028-2029: Validation and Optimization

Q1 2028

- Clinical Trials Results: Publication of detailed results from clinical trials of nanorobots and AI.

- Nanorobots Optimization: Refinement of nanorobots based on initial trial results.

Q2 2028

- Health Systems Integration: Collaboration with global health systems to integrate new technologies.

- Public Education: Campaigns to educate the public about the benefits and use of developed technologies.

Q3 2028

- Certification and Regulation: Working with regulatory bodies for the certification of new medical technologies.

- Production Scaling: Increasing production of nanorobots and robotic devices to meet demand.

Q4 2028

- Global Implementation: Beginning the global implementation of developed technologies.

2029-2030: Realization and Global Adoption

Q1 2029

- Advanced Therapies Launch: Availability of therapies based on nanotechnology and AI to the public.

- Global Access: Ensuring technologies are accessible in various parts of the world, regardless of location.

Q2 2029

- Continuous Improvement: Continuous monitoring and enhancement of deployed technologies.

- Results Communication: Dissemination of the global impacts of longevity technologies.

Q3 2029

- Final Review: Final evaluation of progress towards the immortality goal.

- Preparation for 2030: Strategic planning to achieve immortality by 2040.

Q4 2029

- Innovations Consolidation: Consolidation of all innovations and preparation for the 2030 milestone.

2030-2040: Consolidation and Achieving Immortality

2030-2035

- Clinical Validation and Refinement: Continued clinical validation of rejuvenation therapies and improvement of treatments based on results.

- Production Scaling: Expanding production capacity to meet the growing demand for rejuvenation therapies.

2035-2038

- Global Implementation: Ensuring rejuvenation therapies are available in all countries and regions worldwide.

- Education and Awareness: Ongoing public education on available rejuvenation options and the benefits of immortality.

2038-2040

- Achieving Immortality: Consolidation of all scientific and technological advancements to achieve immortality by 2040.

- Monitoring and Adjustments: Maintaining a continuous monitoring system to ensure the efficacy of rejuvenation therapies and making necessary adjustments.

IMML is committed to leading humanity towards immortality, promoting global collaboration, innovation, and responsible adoption of emerging technologies. Join us on this historic journey towards a future without time limits.